HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer
- 860 Downloads
The HER-2/neu protein is intimately involved with normal cell proliferation and tissue growth and is extensively homologous and related to the epidermal growth factor receptor. HER-2/neu protein expression has been most intensively studied in the context of breast carcinoma, in which its amplification and overexpression correlate with the overall course of disease, and with a poor prognosis, and constitute a predictive factor of poor response to chemotherapy and endocrine therapy. In this study, we investigated the relationship between the expression of HER-2/neu and the clinicopathological characteristics of tumors, including survival. This study was performed with a view toward the future introduction of Herceptin therapy for gastric cancer patients. HER-2/neu overexpression and gene amplification was examined with semiquantitative standardized immunohistochemical staining, chromogenic in situ hybridization (CISH), and fluorescence in situ hybridization (FISH) in 182 gastric cancer patients who underwent curative surgery at the Kangbuk Samsung Hospital. Twenty-nine (15.9%) of 182 patients expressed the HER-2/neu protein by immunohistochemistry. HER-2/neu gene amplification was detected in seven patients by CISH and FISH. Intestinal-type cancers exhibited higher rates of HER-2/neu amplification than did diffuse-type cancers (P < 0.05). Tumors with HER-2/neu amplification were associated with poor mean survival rates (922 vs 3243 days) and 5-year survival rates (21.4% vs 63.0%; P < 0.05). Age, TNM stage, and amplification of HER-2/neu were found to be independently related to survival by multivariate analysis. HER-2/neu amplification may constitute an independent prognostic factor in gastric cancer patients, and patients exhibiting HER-2/neu amplification might constitute potential candidates for new adjuvant therapies which involve the use of humanized monoclonal antibodies.
KeywordsGastric neoplasms HER-2/neu
This study was supported by Samsung Biomedical Research Institute Grant SBRI C-A4-212-1.
- 2.Ministry of Health and Welfare and National Cancer Center (2002) Annual Report of the Korea Central Cancer RegistryGoogle Scholar
- 6.Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
- 7.Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719–726PubMedCrossRefGoogle Scholar
- 24.Sobin LH, Wittekind C (eds) (1997) TNM classification of malignant tumors, 5th ed. Wiley-Liss, New YorkGoogle Scholar
- 25.Fenoglio-Preiser C, Carneiro F, Correa O, et al. (2000) Tumors of the stomach. In: Hamilton SR, Aaltonen LA (eds) World Health Organization classification of tumors, pathology and genetics of tumors of the digestive system. IARC, Lyon, pp 37–52Google Scholar
- 39.Joh JW, Noh DY, Bae CD, Choi KJ, Park JB (1996) Amplification and over-expression of erbB–2 oncogene in primary human breast tumors. Exp Mol Med 28:47–53Google Scholar